Based on our Pharmacor advisory services entitled Methicillin-Resistant Staphylococcus aureus and Community-Acquired Pneumonia, Decision Resources is offering an exclusive Pharmacor analyst call entitled Ceftobiprole’s Non-Approval in the U.S. Changes the Forecast for MRSA and Community-Acquired Pneumonia – Who Will Get the Projected $150 Million? Because this analyst call features major updates, it is ONLY available to purchasers of one or both of these Pharmacor advisory services.

 

This analyst call was held on January 14, 2010. Contact us to learn how you can purchase one or both of these Pharmacor advisory services and access a recorded playback of this event.

Click here to view the invite.